Buy Mounjaro 15mg KwikPen Injection Online

MOUNJARO 15MG KWIKPEN

Name: MOUNJARO 15MG KWIKPEN
Brand: LILLY PRODUCTS
SKU: 95066
Price: 23203.10 INR
Availability: InStock

Item requires a valid prescription

Manufactured By LILLY PRODUCTS

Composition TIRZEPATIDE 15MG

RS 23203.10

MRP RS 25781.20

(10% OFF)

Includes all taxes

Package SIZE

( 2.4ML )

100% Authentic
Products

Free
Shipping*

Products
Return Policy

Information about MOUNJARO 15MG KWIKPEN

Description:

Mounjaro 15mg KwikPen Tirzepatide 15mg is an innovative once weekly subcutaneous injection manufactured by Lilly Products Eli Lilly representing a breakthrough in the treatment of Type 2 Diabetes Mellitus T2DM and weight management As the world 39 s first dual glucose dependent insulinotropic polypeptide GIP and glucagon like peptide 1 GLP 1 receptor agonist Tirzepatide simultaneously activates two incretin hormone pathways delivering superior glycaemic control and clinically significant weight reduction compared to existing injectable therapies The 15mg dose is the highest approved maintenance dose used after dose escalation from lower strengths Available from Shabbir Medical Hall at the best price in India this genuine prescription KwikPen is available online with fast reliable delivery BENEFITS Mounjaro 15mg achieves average HbA1c reductions of up to 2 58 and body weight reductions of up to 15 7 kg in clinical trials SURPASS programme By activating both GIP and GLP 1 receptors it enhances insulin secretion in a glucose dependent manner suppresses glucagon slows gastric emptying and promotes satiety producing a uniquely powerful metabolic effect Its weekly dosing schedule combined with the user friendly KwikPen device makes it highly convenient for patients requiring injectable diabetes therapy USAGE OVERVIEW Mounjaro 15mg is administered as a once weekly subcutaneous injection in the abdomen thigh or upper arm The 15mg dose is reached after gradual dose escalation starting at 2 5mg weekly Always inject on the same day each week The KwikPen is pre filled and ready to use no dose preparation required Never self initiate without physician guidance and proper injection training SAFETY OVERVIEW The most common side effects are gastrointestinal nausea vomiting diarrhoea and reduced appetite particularly during dose escalation Rare but serious risks include pancreatitis gallbladder disease and a theoretical risk of thyroid C cell tumours based on animal data Inform your doctor of all medical conditions and medications before starting

Uses / Indications:

PRIMARY APPROVED USES Type 2 Diabetes Mellitus T2DM Adjunct to diet and exercise to improve glycaemic control in adults Cardiovascular Risk Reduction Mounjaro has demonstrated cardiovascular benefits in T2DM patients with established cardiovascular disease Weight Management Obesity Overweight As Zepbound same molecule Tirzepatide 15mg is approved for chronic weight management in adults with obesity BMI 30 or overweight BMI 27 with at least one weight related comorbidity ADDITIONAL EMERGING USES Non alcoholic steatohepatitis NASH Metabolic Associated Steatotic Liver Disease MASLD under clinical investigation Obstructive sleep apnoea in obesity clinical data emerging Polycystic ovary syndrome PCOS with insulin resistance off label specialist use Heart failure with preserved ejection fraction HFpEF in obese patients clinical trials ongoing

Interactions / Warnings:

THYROID C CELL TUMOUR WARNING In animal studies Tirzepatide caused dose dependent thyroid C cell tumours It is UNKNOWN whether this risk applies to humans Mounjaro is CONTRAINDICATED in patients with a personal or family history of medullary thyroid carcinoma MTC or Multiple Endocrine Neoplasia syndrome type 2 MEN2 Report any neck masses hoarseness or dysphagia immediately PANCREATITIS GLP 1 GIP agonists have been associated with acute pancreatitis Discontinue Mounjaro immediately if pancreatitis is suspected Do not restart without physician evaluation HYPOGLYCAEMIA RISK Mounjaro alone has a low risk of hypoglycaemia Risk increases significantly with concurrent insulin or sulfonylurea use Patients and caregivers should know hypoglycaemia symptoms and management Carry fast acting glucose glucose tablets fruit juice at all times DIABETIC RETINOPATHY Rapid improvement in blood sugar control as seen with Mounjaro may temporarily worsen diabetic retinopathy Patients with pre existing retinopathy require ophthalmological monitoring RENAL DISEASE No dose adjustment required for renal impairment but dehydration from GI side effects can precipitate acute kidney injury Ensure adequate hydration especially during dose escalation HEPATIC DISEASE No dose adjustment required for hepatic impairment Limited data in severe hepatic impairment use with specialist guidance TYPE 1 DIABETES Mounjaro is NOT indicated for Type 1 Diabetes or diabetic ketoacidosis DRIVING MACHINERY Hypoglycaemia especially with insulin co use may impair driving ability Patients should assess their response before driving ELDERLY USE 65 years No age specific dose adjustment but elderly patients may be more susceptible to GI side effects and dehydration Monitor renal function and hydration status closely

Pregnancy interaction:

PREGNANCY SAFETY Mounjaro 15mg Tirzepatide is NOT recommended during pregnancy Animal studies have shown adverse effects on foetal development at clinically relevant doses Tirzepatide should be discontinued at least 2 months before a planned pregnancy Women of childbearing potential must use effective contraception during treatment Inform your doctor immediately if pregnancy is suspected or confirmed during treatment Uncontrolled blood sugar during pregnancy poses significant risks your physician will switch you to insulin which is safe in pregnancy BREASTFEEDING It is not known whether Tirzepatide is excreted in human breast milk Breastfeeding is NOT recommended during treatment with Mounjaro as a precautionary measure Discuss alternative feeding options with your physician CONTRACEPTION WARNING Never stop Mounjaro without consulting your endocrinologist or diabetologist Stopping abruptly without medical supervision may lead to significant deterioration in blood sugar control

Expert advice:

PHARMACIST BEST PRACTICES 1 MANDATORY DOSE ESCALATION NEVER JUMP STRAIGHT TO 15MG Tirzepatide must be dose escalated gradually 2 5mg 5mg 7 5mg 10mg 12 5mg 15mg each step every 4 weeks Starting at 15mg without escalation causes severe GI side effects Always follow the escalation plan your endocrinologist has prescribed 2 MANAGE GI SIDE EFFECTS PROACTIVELY Nausea and vomiting are the most common reasons patients discontinue Tirzepatide Advise eating smaller low fat meals avoiding spicy or greasy food and drinking adequate fluids GI effects typically improve within 4 8 weeks at each dose level 3 WATCH FOR HYPOGLYCAEMIA IF ON INSULIN If you use Mounjaro alongside insulin or a sulfonylurea your doctor may reduce your insulin sulfonylurea dose when initiating or escalating Always carry fast acting glucose Monitor blood sugar more frequently during dose escalation 4 ORAL CONTRACEPTIVE TIMING If you take oral contraceptive pills discuss with your doctor Tirzepatide slows gastric emptying which may reduce OCP absorption Consider additional contraception e g condom during the first 4 weeks of each dose increase 5 COLD CHAIN COMPLIANCE Always store Mounjaro KwikPen in the refrigerator 2 8 C Never freeze If storing out of the fridge use within 21 days and keep below 30 C Use an insulated medical pouch during travel Inspect for cloudiness before each injection do not use if compromised MONITORING ADVICE Blood glucose fasting post prandial Regularly especially during dose escalation HbA1c Every 3 months initially target

Side Effects:

VERY COMMON SIDE EFFECTS 1 in 10 people mostly GI especially during dose escalation Nausea most common particularly at higher doses Vomiting Diarrhoea Constipation Reduced appetite decreased food intake Abdominal pain or discomfort Dyspepsia indigestion COMMON SIDE EFFECTS 1 in 10 to 1 in 100 people Injection site reactions erythema bruising swelling pruritus Fatigue and dizziness especially early in treatment Hypoglycaemia low blood sugar particularly if used with insulin or sulfonylureas Hair loss alopecia often related to rapid weight loss Belching and flatulence Elevated heart rate mild SERIOUS SIDE EFFECTS CONTACT DOCTOR IMMEDIATELY Acute Pancreatitis sudden severe upper abdominal pain radiating to the back nausea vomiting discontinue Mounjaro and seek urgent care Gallbladder Disease cholecystitis cholelithiasis right upper abdominal pain fever jaundice Severe hypoglycaemia shakiness confusion cold sweats unconsciousness higher risk if on insulin Severe gastrointestinal events ileus gastroparesis rare Acute kidney injury secondary to severe dehydration from prolonged GI side effects EMERGENCY WARNING SIGNS SEEK IMMEDIATE MEDICAL HELP Sudden severe abdominal pain with vomiting possible pancreatitis Signs of severe allergic reaction facial swelling difficulty breathing rapid heartbeat anaphylaxis Neck mass hoarseness or difficulty swallowing possible thyroid tumour rare Severe dehydration dizziness dark urine inability to keep fluids down

How to use:

DOSAGE GUIDANCE mandatory always follow physician s plan DOSE ESCALATION SCHEDULE Week 1 4 2 5mg once weekly starting dose not therapeutic for tolerability Week 5 8 5mg once weekly Week 9 12 7 5mg once weekly Week 13 16 10mg once weekly Week 17 20 12 5mg once weekly Week 21 15mg once weekly maximum maintenance dose ROUTE OF ADMINISTRATION HOW TO USE THE KWIKPEN Remove KwikPen from refrigerator 30 minutes before use and allow to reach room temperature Inspect solution it should be clear colourless to slightly yellow do not use if cloudy or containing particles Select injection site abdomen at least 5cm from navel outer thigh or upper arm Clean the skin with an alcohol swab and allow to dry Press the KwikPen firmly against skin press and hold the button until the injection is complete click sound then hold for 5 more seconds Rotate injection sites weekly to prevent skin reactions TIMING Inject once every 7 days on the same day each week Can be taken at any time of day with or without food MISSED DOSE If a dose is missed and the next dose is 4 days away inject as soon as remembered If next dose is

How it works:

DUAL RECEPTOR MECHANISM Mounjaro 15mg KwikPen contains Tirzepatide the world s first dual GIP GLP 1 receptor agonist a novel molecule engineered by Eli Lilly using a fatty acid linker that enables once weekly dosing 1 GLP 1 Receptor Agonism Stimulates glucose dependent insulin secretion from pancreatic beta cells Suppresses glucagon release from alpha cells reducing hepatic glucose output Slows gastric emptying blunting post meal blood glucose spikes Promotes central satiety via hypothalamic GLP 1 receptors reducing appetite and caloric intake 2 GIP Receptor Agonism unique vs GLP 1 mono agonists like semaglutide Enhances insulin secretion synergistically with GLP 1 signalling Promotes adipocyte lipid metabolism enhancing fat utilisation Improves insulin sensitivity in peripheral tissues muscle adipose tissue May reduce GLP 1 associated nausea burden through GIP mediated pathways CLINICAL OUTCOME Average HbA1c reduction up to 2 58 SURPASS 2 vs semaglutide 1mg Average body weight reduction up to 15 7 kg at 15mg dose SURPASS 4 Superior to semaglutide 1mg in both HbA1c and weight endpoints in head to head trials Cardiovascular outcome data positive with reduction in MACE risk in high CV risk T2DM patients

Faq for medicine:

1 What makes Mounjaro 15mg KwikPen the maximum approved Tirzepatide dose Mounjaro 15mg KwikPen delivers the highest approved dose of Tirzepatide 15mg weekly providing the maximum glycaemic and weight management benefits in the SURPASS clinical program At 15mg HbA1c reductions of up to 2 3 and weight loss exceeding 12 15 of body weight were demonstrated Mounjaro 15mg is reserved for patients who have tolerated 12 5mg and require further metabolic improvement 2 How significant is weight loss with Mounjaro 15mg KwikPen compared to lower doses Mounjaro 15mg KwikPen produces the most substantial weight loss of all Tirzepatide doses In the SURMOUNT 1 trial non diabetic participants on 15mg lost an average of 20 9 of body weight over 72 weeks In type 2 diabetes patients Mounjaro 15mg delivers approximately 12 15 kg weight reduction This level of weight loss is clinically comparable to bariatric surgery outcomes in some patient populations 3 What should patients know about thyroid cancer risk with Mounjaro 15mg KwikPen Mounjaro 15mg KwikPen carries a warning regarding thyroid C cell tumors based on rodent studies showing GLP 1 receptor agonists caused thyroid tumors in animals It is unknown if this risk applies to humans Mounjaro 15mg is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 Patients should report any neck lumps difficulty swallowing or persistent hoarseness to their physician 4 Can Mounjaro 15mg KwikPen be used alongside basal insulin in diabetes Mounjaro 15mg KwikPen can be combined with basal insulin but insulin doses typically need reduction to prevent hypoglycaemia In clinical trials adding Tirzepatide to insulin significantly improved HbA1c while enabling meaningful insulin dose reduction Physicians carefully titrate insulin downward when initiating Mounjaro 15mg Blood glucose self monitoring is essential during combination therapy initiation to maintain safe glucose levels 5 What happens if a weekly Mounjaro 15mg KwikPen dose is missed If a Mounjaro 15mg KwikPen dose is missed administer it as soon as possible within 4 days of the missed injection If more than 4 days have passed skip the missed dose and resume the regular weekly schedule Do not take two doses within 3 days of each other Blood glucose levels may temporarily rise with a missed dose so patients with type 2 diabetes should monitor closely and consult their physician 6 Are pancreatitis risks higher with Mounjaro 15mg than with lower doses Tirzepatide including Mounjaro 15mg KwikPen carries a class level risk of acute pancreatitis associated with GLP 1 receptor agonists Risk does not appear dose dependent but caution is advised in patients with prior pancreatitis Symptoms including persistent severe abdominal pain radiating to the back should prompt immediate discontinuation and medical evaluation Mounjaro 15mg is contraindicated in patients with a confirmed history of pancreatitis

Medicine interaction:

DRUG INTERACTIONS inform your doctor and pharmacist of ALL medicines INSULIN INSULIN SECRETAGOGUES HIGH RISK dose adjustment required Insulin all types rapid basal mixed concurrent use significantly increases hypoglycaemia risk Sulfonylureas glibenclamide glipizide glimepiride enhanced hypoglycaemia risk consider dose reduction of sulfonylurea when initiating Mounjaro ORAL MEDICATIONS WITH NARROW THERAPEUTIC INDEX Tirzepatide slows gastric emptying may alter absorption timing and peak levels of oral drugs Warfarin oral anticoagulants monitor INR closely onset of absorption may be delayed Oral contraceptives reduced absorption possible consider using non oral contraception or additional barrier methods during first 4 weeks of each dose escalation step Levothyroxine digoxin monitor levels absorption kinetics may be affected ANTIHYPERTENSIVES Significant weight loss with Tirzepatide may reduce blood pressure antihypertensive doses may need to be adjusted to avoid hypotension LIPID LOWERING MEDICINES Weight loss may improve lipid profiles statin or fibrate doses may require review over time VACCINE INTERACTIONS Alcohol increases hypoglycaemia risk particularly with insulin co administration Alcohol may worsen GI side effects limit consumption during treatment SUPPLEMENT INTERACTIONS No major documented interactions but always inform your pharmacist of all supplements and herbal products some may affect blood sugar or GI function